Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|
Operating Income | $0.0 | ($69.2M) | ($63.6M) | ($203.2M) | ($94.1M) | $18.1B | $13.3B | $746.6M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, BioNTech SE's last 12-month Operating Income is ($1,016.3M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, BioNTech SE's Operating Income growth was N/A. The average annual Operating Income growth rates for BioNTech SE have been N/A over the past three years, 47.1% over the past five years.